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Dual inhibition of Type I and Type III PI3
kinases increases tumor cell apoptosis in
HER2+ breast cancers
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Abstract
Introduction: Human epidermal growth factor receptor-2 (HER2) gene amplification (HER2+) drives tumor cell
growth and survival in ~25 % of breast cancers. HER2 signaling activates the type I phosphoinositide 3-kinase (PI3K),
upon which these tumors rely. Consequently, inhibitors of HER2 and type I PI3K block growth and increase
apoptosis in HER2+ breast cancers, especially when used in combination. However, the impact of type III PI3K
inhibition, particularly in combination with HER2 blockade or type I PI3K inhibition, remains less clear.
Methods: We utilized small molecule kinase inhibitors, locked nucleic acid antisense oligonucleotides (LNA-ASOs),
and siRNA to assess proliferation, autophagy, apoptosis, and protein expression in cell culture models of HER2+
breast cancers.
Results: Treatment of HER2+ breast cancer cells with HER2 inhibitors or type I PI3K kinase inhibitors, alone or in
combination, blocked type I PI3K signaling, reduced tumor cell growth, and induced autophagy. Knockdown of the
type I PI3K, p110α, using an LNA-ASO termed EZN4150 inhibited PI3K-mediated Akt phosphorylation. However, in
contrast to catalytic inhibitors of type I PI3Ks, EZN4150 did not induce autophagy, and blocked autophagy in
response to inhibitors of HER2 or type I PI3Ks in a dominant fashion. Sequence analysis of EZN4150 revealed
significant homology to the gene encoding the type III PI3K, Vps34, a key component for autophagy induction.
EZN4150 simultaneously reduced expression of both p110α and Vps34. Combined inhibition of PI3K signaling and
autophagy using individual siRNAs against p110α and Vps34 or using pharmacological type I and type III PI3K
inhibitors recapitulated what was seen with EZN4150, and robustly enhanced tumor cell killing.
Conclusions: These studies highlight the important role of Vps34-mediated autophagy in limiting the anti-tumor
response to inhibitors of HER2 or type I PI3K in HER2+ breast cancers. The type III PI3K Vps34 represents a potential
therapeutic target to block treatment-induced autophagy and enhance tumor cell killing.
Introduction
Breast cancer afflicts over one million individuals, caus-
ing death in nearly a half million people worldwide every
year [1]. Breast cancer is subdivided into three clinical
subtypes: estrogen receptor positive (ER+), human epi-
dermal growth factor receptor-2 (HER2) positive (HER2+)
and triple negative. Because ER and HER2 are important
drivers of breast cancer, molecularly targeted therapies
against these proteins and their signaling pathways are
approved for treatment of patients with these cancer
subtypes.
The HER2 tyrosine kinase (RTK) heterodimerizes with
a related RTK, ErbB3, to activate several signal transduc-
tion pathways, including the type I phosphoinositide 3-
kinase (PI3K) pathway, specifically the p110α catalytic
subunit of PI3K [2]. Conditional gene targeting of ErbB3
or p110α in the mammary gland abrogates HER2-
mediated tumor formation in genetically engineered
mice [3, 4]. Similarly, loss of Akt1, a key p110α effector,
impairs HER2-induced mammary tumorigenesis in mice,
underscoring the importance of the effectors down-
stream of HER2 and p110α [5, 6]. In contrast, the p110β
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isoform of type I PI3K plays a dominant role in phos-
phatase and tensin homolog (PTEN)-null breast tumors,
but is not required for growth in many HER2-amplified
breast cancers [7]. Importantly, type I PI3K inhibitors
potently reduce growth of HER2+ tumor cells in culture
and in vivo, and combinations of type I PI3K and HER2
inhibitors display superior anti-tumor activity against
HER2+ cancers, suggesting that multiple signaling nodes
in the HER2/PI3K pathway require inhibition to abro-
gate feedback PI3K re-activation that often occurs in re-
sponse to single-agent inhibition [8–13].
A key downstream effector of PI3K/Akt is mTOR, a
kinase that increases cellular energy consumption to
drive anabolic processes including protein translation
and lipid synthesis to support tumor cell proliferation
[14]. In contrast, catabolic processes like autophagy are
activated in response to lowered cell energetics under
the regulation of AMPK, which phosphorylates ULK1,
Vps34/class III PI3K and other regulatory factors [15].
By competing with AMPK for phosphorylation of au-
tophagy regulatory factors, mTOR reduces autophagy
[16–18]. Conversely, autophagy is induced upon block-
ade of mTOR or factors upstream of mTOR, transiently
supporting cell survival and reducing the anti-tumor
impact of therapeutic inhibitors of HER2, type I PI3Ks,
and mTOR [17, 19]. Tumor cell death in response to
mTOR inhibition is enhanced by the use of autophagy
inhibitors [20–23].
Herein, we demonstrate that combined targeting of
type I (p110α) and type III (Vps34) PI3Ks using a single
locked nucleic acid antisense oligonucleotide (LNA-ASO)
sequence with homology to both transcripts, or using
pharmacological inhibitor to each, attenuated signaling
through Akt/mTOR, yet prevented autophagy
induction typically seen upon mTOR inhibition. As a re-
sult, combined inhibition of p110α and Vps34 markedly
increased tumor cell killing, and improved tumor growth
inhibition in response to HER2 inhibitors. Our results
support the utility of inhibiting autophagy when using
HER2 or PI3K inhibitors and identify a single oligonucleo-




Commercially purchased antibodies and siRNA are listed
in Table 1. Cell culture reagents including fetal bovine
serum (FBS) were purchased from Life Technologies
(Grand Island, NY, USA). EZN4150 (targeting p110α)
and EZN3046 (non-targeting scrambled control for
EZN4150) were provided by Enzon pharmaceuticals
(Piscataway, NJ, USA). BYL719 and BKM120 were pro-
vided by Novartis (Cambridge, MA, USA). Lapatinib was
purchased from LC laboratories (Woburn, MA, USA).
SAR405 was purchased from ApexBio (Houston, TX,
USA). pBABEpuro GFP-LC3 was a gift from Jayanta
Debnath (Addgene plasmid # 22405).
Cell culture, siRNA transfection and virus production
All cells were obtained from ATCC (Manassas, VA,
USA) and maintained in DMEM supplemented with
10 % FBS. LNA-ASO compounds were applied to cells
at 5 μM (unless otherwise noted) without transfection
reagent, replenishing in fresh media every 3–4 days in
studies exceeding four days. siRNA complexes were pre-
pared at 500 nM in OptiMEM and diluted 10-fold into
culture media for a final concentration of 50 nM. For
example, 100 μl of 500 nM siRNA was prepared by
Table 1 Antibodies and siRNAs
Antibody Vendor Catalog number Dilution siRNA Vendor Catalog number
p110α Cell Signaling 4249 1:1,000 Universal neg ctrl Sigma SIC003
p110β Cell Signaling 3011 1:1,000 p110α-silencing Sigma SASI_Hs01_00219338
P-Akt (S473) Cell Signaling 9271 1:1,000 p110α-silencing Sigma SASI_Hs01_00219339
Akt Cell Signaling 9272 1:2,000 Vps34-silencing Sigma SASI_Hs01_00233716
P-S6 (S235/6) Cell Signaling 4858 1:1,000 Vps34-silencing Sigma SASI_Hs02_00334179
S6 Cell Signaling 2317 1:1,000
P-HER2 (Y1221) Cell Signaling 2243 1:1,000
HER2 Thermo Rb103 1:1,000
Vps34 Cell Signaling 3358 1:1,000
LC3 Cell Signaling 4108 1:1,000
Actin Cell Signaling 4970 1:5,000
PARP Cell Signaling 9532 1:1,000
Cleaved caspase 3 Cell Signaling 9661 1:500
HER2 human epidermal growth factor receptor-2, PARP poly(ADP-ribose) polymerase Cell Signaling Technologies (Danvers, MA, USA). Thermo-Fisher (Waltham, MA,
USA). Sigma-Aldrich (St. Louis, MO, USA)
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mixing 2.5 μl of 20 μM siRNA and 3 μl Lipofectamine
RNAiMAX in a final volume of 100 μl OptiMEM, allow-
ing complexes to form for 15 minutes and then applying
them to cells in 900 μl of media for a final 50 nM
siRNA. When two siRNAs were combined, each was ap-
plied at a final concentration of 50 nM and non-
targeting control siRNA was used in combination with
targeting siRNA such that all cells received a total of
100 nM siRNA. Amphotropic retrovirus was generated
by transfecting 24 μg proviral plasmid into Phoenix-
Ampho cells in 10-cm dishes using 60 μl Lipofectamine
2000. Packaging cells were fed 24 h post-transfection;
virus-containing supernatants were harvested 48 and 72 h
post-transfection, diluted 1:4 and applied to target cells
with 8 μg/ml polybrene. Target cells were selected with
1 μg/ml puromycin.
Proliferation, caspase 3/7 and annexin-V assays
Proliferation assays were performed by plating 5 × 104
cells/well of 6-well plates or 2 × 104 cells/well of 12-well
plates and treating with LNA-ASO compounds as indi-
cated. Fresh media and compounds were applied every
3 days. Cells from triplicate wells of each treatment group
were trypzinised and counted with a TC10 hemo-
cytometer (Biorad; Hercules, CA, USA) on the indicated
days. Alternatively, 5 × 103 cells/well were seeded in 96-
well plates, treated as described and relative proliferation
determined by sulforhodamine B (SRB) assay or DNA
quantification. Briefly, media were decanted and mono-
layers fixed with 10 % TCA, washed with tap water, dried,
stained with 0.4 % SRB in 1 % acetic acid, de-stained with
1 % acetic acid, dried, solubilized with 10 mM Tris base
and quantitated by spectrophotometric detection at
490 nm using a plate reader. Proliferation is presented
relative to the control treated cells or the day-0 value. For
caspase 3/7 activity and annexin V staining, cells seeded in
96-well plates were pretreated for 30 minutes with di-
methyl sulfoxide (DMSO) control or 1 μM SAR405 30 mi-
nutes before being treated with DMSO control, 0.5 μM
BYL719 or 0.5 μM lapatinib. Cells were lysed with an
equal volume of caspase 3/7 reagent (Promega; Fitchburg,
WI, USA) after the indicated time point (3, 6, 12 or 24 h),
incubated for 45 minutes and luminescent caspase 3/7 ac-
tivity was assessed on a 96-well plate luminometer. For
annexin V staining, cells were treated similarly (BT474
and UACC893 for 6 h, SKBR3 for 24 h) with 5 μl of Alexa-
Fluor 594-conjugated annexin V added 1 h and 1 μg/ml
Hoescht 33342 added 15 minutes before the end of treat-
ment. Images were captured with an ImageExpress 96-
well plate fluorescent microscope (Molecular Devices;
Sunnyvale, CA, USA) with nine × 10 images captured per
well of quadruplicate wells. The total number of nuclei
and number of annexin V-positive cells was determined
with MetaXpress software and is presented as the percent-
age of annexin V-positive cells.
Immunoblot
Lysates were generated by removing media from cells,
washing monolayers with cold PBS and lysis with
RIPA: 50 mM Tris, pH 7.4, 150 mM NaCl, 1 % NP-
40, 0.5 % Deoxycholate, 0.1 % SDS, 1 mM EDTA,
50 mM NaF, 1 mM NaVO4 and 1 × protease inhibitor
cocktail (Roche). Lysates were clarified by centrifuga-
tion at 15,000 × g for 15 minutes. Protein concentra-
tion was determined by bicinchoninic acid (BCA)
assay (Thermo scientific; Waltham, MA, USA). For
immunoblot analysis, equal amounts of protein/lane
were subjected to SDS-PAGE, transferred to nitrocel-
lulose membranes and analyzed with the antibodies
detailed above.
Statistical analyses
GraphPad Prism was used for statistical analyses. For
two-group analyses, the Student t test was conducted. In
analyses of more than two groups, analysis of variance
(ANOVA) was conducted with Tukey multiple compari-
son analyses to compare individual groups. Error bars
represent standard error of the mean (SEM).
Results
EZN4150 reduces p110α expression, PI3K signaling and
growth in HER2+ breast cancer cells
We used LNA-ASOs to inhibit the PI3K signaling axis
in HER2+ breast cancer cells. Unlike kinase inhibitors,
which generally block ATP-dependent enzymatic activ-
ity, ASOs bind to and downregulate transcripts encoding
any chosen gene product, including “non-druggable” tar-
gets (e.g., adaptor molecules, transcription factors, or
cancer-specific mutant transcripts) [24, 25]. For example,
EZN3920 is an ErbB3-directed LNA-ASO which po-
tently inhibits growth and survival of HER2+ tumor cells
both in vitro and in vivo [25–27]. We used EZN4150, an
LNA-ASO directed against the PIK3CA gene, encoding
the p110α type I PI3K catalytic subunit. HER2+ breast
cancer cells (MDA-MB-361, BT474 and SKBR3) were
treated with escalating doses of EZN4150 or with
EZN3046, a scrambled non-targeting control LNA-ASO.
EZN4150 produced a dose-dependent reduction in p110α
expression in all three cell lines, with maximal p110α
knock-down at 5 μM (Additional file 1: Figure S1A).
EZN4150 reduced expression of p110α but not p110β,
demonstrating the isoform specificity of EZN4150
(Additional file 1: Figure S1B). EZN4150 reduced P-Akt in
MDA-MB-361, BT474 and SKBR3 cells, but did not affect
P-Akt in PTEN-deficient HCC1937 cells, consistent with
previous observations that PTEN-deficient breast cancer
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cells preferentially rely on p110β, not p110α, for type I
PI3K signaling [3, 7].
We examined the impact of EZN4150 on growth of
SKBR3, BT474 and UACC893 HER2+ cells. EZN4150
treatment for 12 days decreased SKBR3 cell numbers
>10-fold as compared to EZN3046 treatment (Fig. 1a),
while decreasing phosphorylation of Akt (Fig. 1b), thus
demonstrating inhibition of PI3K signaling. Decreased
phosphorylation of S6, a distal effector of mTOR signaling,
was also observed in SKBR3 cells treated with EZN4150.
Increased caspase 3 cleavage in response to EZN4150
suggested that targeted downregulation of p110α using
EZN4150 may induce tumor cell death. Similarly,
EZN4150-mediated p110α downregulation significantly
decreased the number of BT474 cells after 10 days of
treatment, and decreased Akt phosphorylation (Fig. 1c-d).
The HER2+ cell line UACC893 displayed modest but sig-
nificant diminution of tumor cell numbers after 16 days in
culture with EZN4150. Interestingly, Akt phosphorylation
was not impacted by EZN4150 in UACC893 cells, despite
robust p110α downregulation, perhaps explaining the de-
creased responsiveness of UACC893 cells to EZN4150
relative to BT474 or SKBR3 (Fig. 1e-f). In contrast,
PTEN-null ZR75.1 cell numbers and P-Akt were not im-
pacted by EZN4150 (Fig. 1g-h), consistent with the idea
that PTEN-null cells preferentially use p110β for Akt acti-
vation and cell survival.
Inhibition of tumor cell growth in response lapatinib and
BKM120 is enhanced by EZN4150
To determine the impact of EZN4150-mediated p110α
ablation on HER2+ tumor cell response to the EGFR/
HER2 tyrosine kinase inhibitor (TKI) lapatinib [28], we
treated SKBR3, BT474, and UACC893 cells with EZN4150
in the presence or absence of lapatinib. While lapatinib in-
duced low levels of caspase 3 cleavage in all three cell
lines, the addition of EZN4150 increased cleaved caspase
3 and decreased P-Akt to a greater extent than was seen
with either agent alone (Fig. 2a). Like EZN4150-mediated
p110α ablation, catalytic inhibition of PI3K using the pan-
type I PI3K inhibitor BKM120 [29] decreased P-Akt in all
three cell lines, but did not induce cleavage of caspase 3.
However, EZN4150 in combination with BKM120 de-
creased P-Akt to a greater degree than either EZN4150 or
BKM120 alone, and increased cleaved caspase 3 levels to a
greater extent than either single compound in all three cell
lines, suggesting that the effects of EZN4150 are not en-
tirely identical to the effects achieved using catalytic PI3K
inhibition. Further, these results suggest that EZN4150 en-
hanced lapatinib-mediated or BKM120-mediated caspase
3 activation.
Inhibition of PI3K/mTOR signaling is known to in-
duce autophagy, a process in which cytoplasmic contents
are degraded in order to maintain cellular energy bal-










































































































Fig. 1 EZN4150 inhibits proliferation of human epidermal growth factor receptor-2 positive (HER2+) breast cancer cells. a, b SKBR3 cells were
treated with the 5 μM EZN3046 (scrambled control locked nucleic acid antisense oligonucleotide (LNA-ASO)) or EZN4150 (p110α targeted LNA-ASO).
a Proliferation was assessed on day 12 of treatment. b Lysates were prepared for immunoblot analysis on day 9. c, d BT474 cells were treated as shown
in a and b. Cells were counted (c) or lysed for immunoblot analysis (d) after 10 days of treatment. e, f UACC893 cells were treated as shown in panels
a and b. e Relative cell number was determined on day 16 of treatment by sulforhodamine B assay. f Cells were lysed for immunoblot analysis after
12 days of treatment. g, h ZR75.1 cells were treated with the 5 μM EZN3046 or EZN4150. g Relative proliferation was determined by quantifying DNA
in each well after 12 days of treatment. h After 10 days of treatment, cells were lysed and analyzed by immunoblot analysis (*p <0.05, Student t test).
Cl. Casp3 cleaved caspase 3
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BKM120 induced autophagy in SKBR3 cells, as indicated
by the decreased presence of the higher molecular-
weight species of LC3 (LC3I) (Fig. 2b), which is modified
to a lower molecular-weight species (LC3II) and subse-
quently degraded upon induction of autophagy. Similarly,
LC3I diminution was seen in UACC893 and BT474 cells
treated with BKM120 as compared to control-treated cells
(Fig. 2a). Lapatinib similarly induced diminution of LC3I
in UACC893 and BT474 cells. However, cells treated with
EZN4150 did not display LC3I diminution, even in the
presence of BKM120 or lapatinib (Fig. 2a, b). These results
thus distinguish the effects of p110α-targeting using
EZN4150 from those using BKM120. Specifically, these
results suggest that autophagy is induced in response to
HER2 inhibition and/or type I PI3K inhibition, but is
blocked by EZN4150, despite its ability to block type I
PI3K kinase activity.
These results were confirmed in SKBR3 and UACC893
cells expressing green fluorescent protein (GFP)-tagged
LC3, which will accumulate to form GFP+ puncta on
the surface of autophagosomes once autophagy is in-
duced. HER2/PI3K inhibition with lapatinib increased
GFP-LC3 puncta in SKBR3 and UACC893 cells (Fig. 2c).
Similarly, LC3-GFP puncta were seen in cells treated
with BKM120, but not with etoposide, demonstrating





























































































































Fig. 2 The inhibition of human epidermal growth factor receptor-2 positive (HER2+) breast cancer cells in response to lapatinib and BKM120 is
enhanced by EZN4150. a SKBR3 were cultured for 6 days, UACC893 cells were cultured for 7 days and BT474 cells were cultured for 9 days with
5 μM EZN3046 or EZN4150. In the final 12 h, dimethyl sulfoxide (DMSO), 1 μM Lapatinib (Lap), 1 μM BKM120 (BKM) or 50 μM etoposide (Etop) was
added. Lysates were harvested and analyzed by immunoblot. b SKBR3 cells were cultured for 6 days with 5 μM EZN3046 or EZN4150 or for 3 days
with 500 nM BKM120 (BKM). Lysates were harvested and analyzed by immunoblot with the indicated antibodies. c SKBR3 GFP-LC3 cells and
UACC893 GFP-LC3 cells were cultured as described in a. Green fluorescent protein (GFP)-LC3 (green) localization was captured by fluorescent mi-
croscopy. d, e SKBR3 GFP-LC3 cells were cultured for 5 days with DMSO, 500 nM BKM120 or 500 nM BYL719. Cells were treated with DMSO (D) or
1 μM Lapatinib (L) for the final 18 h. d Lysates of cells were evaluated by immunoblot analysis with the indicated antibodies. e GFP-LC3
localization was captured by fluorescent microscopy
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blockade rather than to a generalized induction of cell
death. In contrast to what was seen with BKM120-
mediated inhibition of type I PI3K signaling, EZN4150
used as a single agent did not induce the formation of
GFP-LC3 puncta. Further, EZN4150 blocked LC3-GFP+
autophagosome formation in lapatinib-treated cells
and in BKM120-treated cells, again suggesting that
EZN4150 exerts an impact on HER2+ cells that is
separable from what is achieved by the catalytic type I
PI3K inhibitor.
Because EZN4150 requires extended treatment to
achieve p110α knockdown, it is possible that EZN4150
inhibits autophagy through prolonged downregulation of
p110α (5–10 days), as opposed to acute inhibition (12–
24 h) of catalytic type I PI3K activity by BKM120 or
lapatinib. However, even after 5 days of treatment with
BKM120 or BYL719 (a p110α-specific PI3K inhibitor
[30]) to produce sustained inhibition of PI3K signaling
through the type I PI3K pathway (Fig. 2d), GFP-LC3+
autophagosomes were abundant as compared to what
was seen in cells treated with DMSO (Fig. 2e). Lapatinib
treatment for the final 24 h of culture further increased
LC3-GFP+ autophagosomes in SKBR3 cells pre-treated
for 5 days with BKM120 or BYL719. These findings sug-
gest that both acute and sustained PI3K inhibition in-
duces autophagy, and that prolonged PI3K inhibition did
not exhaust or reduce autophagosome formation.
Dual inhibition of p110α and Vps34 by EZN4150
The induction of autophagy by inhibition of the catalytic
activity of type I PI3K with BYL719 or BKM120 is
consistent with the idea that PI3K/mTOR inhibition re-
lieves mTOR-mediated repression of autophagy. How-
ever, the failure of EZN4150 to induce autophagy,
despite strong downregulation of type I PI3K signaling,
suggested two possible scenarios: 1) p110α has a direct
but non-enzymatic role in autophagy induction, (a struc-
tural function, for example); or 2) EZN4150 impacts au-
tophagy in a p110α-independent manner. To distinguish
these possibilities, we knocked down p110α using siRNA
sequences against regions of PIK3CA distinct from
the sequence targeted by EZN4150 (Additional file 2:
Figure S2). Similar to what was seen with EZN4150,
downregulation of p110α by two independent siRNA se-
quences (si38 and si39) reduced P-Akt, as compared to a
control siRNA sequence (Fig. 3a). Unlike EZN4150,
siRNA-mediated p110α knockdown induced GFP-LC3+
autophagosome formation in SKBR3 cells, similar to what
was seen using the catalytic p110α inhibitor BYL719
(Fig. 3b). Further, p110α siRNAs failed to block lapatinib-
induced GFP-LC3 autophagosome formation in SKBR3
cells, in contrast to what was seen using EZN4150 in com-
bination with lapatinib. These results suggested that
EZN4150 may block autophagy through a mechanism that
is independent of p110α downregulation.
Sequence analysis demonstrated that the 16 bp EZN4150
nucleotide sequence matched perfectly (16/16 bp) with
the DNA sequence encoding human PIK3CA, but also
matched 14/16 bp to the human PIK3C3 gene sequence,
which encodes the class III PI3K Vps34. Importantly,
Vps34 lipid kinase activity is necessary for induction of au-
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Fig. 3 EZN4150 inhibits p110α and Vps34. a, b SKBR3 green fluorescent protein (GFP)-LC3 cells were transfected with 50 nM control non-targeting
siRNA (siCTL) or two siRNA sequences targeting PIK3CA (si38 and si39) and cultured for 4 days. Parallel plates were cultured for 4 days with dimethyl
sulfoxide (DMSO) or 500 nM BYL719. Cells were treated with DMSO control (D) or 1 μM Lapatinib (L) for the final 18 h. a Lysates of cells were evaluated
by immunoblot analysis with the indicated antibodies. b GFP-LC3 localization was captured by fluorescent microscopy. c Alignment of the EZN4150
sequence with the sequences of human PIK3CA and PIK3C3, the genes encoding p110α and Vps34, respectively. Misaligned bases are underlined in
bold. d Cells were treated with 5 μM EZN3046 or EZN4150 for 7–8 days. Lysates were analyzed by immunoblot with the indicated antibodies
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EZN4150 downregulated both p110α and Vps34 expres-
sion in SKBR3, BT474, and UACC893 cells (Fig. 3d).
Thus, the inhibition of autophagy by EZN4150 may be
mediated by Vps34 ablation [31], which we explored in
additional experiments.
To determine the combined impact of siRNA-mediated
knockdown of Vps34 and p110α, siRNA sequences were
used to knock down Vps34 alone, p110α alone, or Vps34
and p110α together. While siRNA sequences targeting
p110α inhibited growth of HER2-amplified SKBR3, BT474,
and UACC893 cells, siRNA sequences targeting Vps34
had little impact on SKBR3 and UACC893 cell growth,
and had modest inhibition of BT474 cell growth (Fig. 4a).
However, the combined siRNA-mediated knockdown of
p110α and Vps34 significantly decreased SKBR3 and
BT474 cell numbers more potently than either siRNA
alone. Western analysis revealed only partial knockdown
of both Vps34 and p110α by the siRNA sequences, indu-
cing only a modest reduction in P-Akt in all three cell
lines (Fig. 4b), unlike the robust p110 knockdown and
P-Akt reduction seen using EZN4150. Despite only partial
knockdown, p110α or Vps34 siRNA increased cleaved
caspase 3 and cleaved PARP in UACC893 cells.
The impact of combined p110α and Vps34 knockdown
on lapatinib-mediated growth inhibition was examined
by treating the cells for the final 24 h of culture with
lapatinib. Lapatinib-mediated growth inhibition was ob-
served in SKBR3, BT474, and UACC893 cells, which
was enhanced upon knockdown of either p110α or
Vps34 in BT474 and UACC893 cells, albeit modestly
(Fig. 4a). The combined knockdown of Vps34 and p110α
significantly enhanced lapatinib-mediated growth inhibition
in BT474 and SKBR3 cells. Increased lapatinib-mediated
cleavage of caspase 3 and/or PARP was seen upon com-
bined knockdown of p110α and Vps34 as compared to
knockdown of either factor alone in BT474 cells (Fig. 4b).
Regardless of siRNA treatment, lapatinib induced high
levels of caspase 3 and PARP cleavage in UACC893 cells
and very little cleavage in SKBR3 cells. However, slightly
increased levels of PARP cleavage were detected in SKBR3
cells with combined knockdown of Vps34 and p110α and

































































































































































Fig. 4 Simultaneous reduction of p110α and Vps34 reduces proliferation and sensitizes human epidermal growth factor receptor-2 positive (HER2+)
cells to lapatinib. UACC893, BT474 and SKBR3 cells were transfected with siRNA at a final concentration of 100 nM, 50 nM each: 1) siCTRL + siCTRL
(CTRL); 2) siVps34 + siCTRL(V34); 3) sip110α + siCTRL(p110); 4) siVps34 + sip110α (V + p). Three days post-transfection, cells were treated with dimethyl
sulfoxide (DMSO) control or 1 μM lapatinib (Lap). a Relative cell number was assessed 24 h after lapatinib treatment by sulforhodamine B assay. Within
each drug treatment (DMSO or Lap): *p <0.05 comparing siCTRL + siCTRL to the other three combinations; #p <0.05 comparing single targeted siRNA
to siVps34 + sip110; one way analysis of variance with Tukey multiple comparison test. Student t test analysis of each DMSO/lapatinib pair was
significant (p <0.05), and is not graphically depicted. b Lysates were harvested 2 h after lapatinib treatment and were analyzed by immunoblot with
the indicated antibodies. PARP poly(ADP-ribose) polymerase, C Casp 3 cleaved caspase 3
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combined knockdown of p110α and Vps34 using
siRNA can induce caspase and PARP cleavage, and en-
hance lapatinib-mediated growth inhibition in HER2+
breast cancer cells, consistent with what was seen using
EZN4150.
Combined inhibition of HER2, Vps34 and/or p110α
induces cell death in HER2+ breast cancer
To confirm these results, we used a small molecular-
weight kinase inhibitor of Vps34, SAR405, alone and in
combination with inhibitors for p110α and/or HER2.
Importantly, Vps34 inhibition using SAR405 has been
shown to block the induction of autophagy in response
to mTOR inhibition [32]. Similar to what was seen upon
siRNA-mediated Vps34 knockdown, Vps34 inhibition
using SAR405 had only modest anti-proliferative effects
as a single agent in HER2-amplified breast cancer cells
(Fig. 5a), and no impact on phosphorylation of Akt
(Fig. 5b). However, SAR405 enhanced lapatinib-mediated
growth inhibition and BYL719-mediated growth inhibition
in SKBR3, BT474, and UACC893 cells (Fig. 5a). SKBR3,
BT474, and UACC893 cells demonstrated >90 % decrease
in relative cell number when lapatinib, BYL719, and
SAR405 were used in combination.
The impact of SAR405-mediated Vps34 inhibition on
autophagy was examined by western analysis of LC3.
While lapatinib and BYL719 each resulted in the dimin-
ution of LC3I and/or accumulation of LC3II in the three
HER2-amplified cell lines tested, SAR405 robustly blocked
LC3I diminution and LC3II accumulation (Fig. 5b), con-
sistent with the hypothesis that Vps34 blockade efficiently
dampens induction of autophagy upon p110α inhibition.
These results were confirmed by fluorescent imaging,
examining autophagosomal accumulation of GFP-tagged
LC3 in UACC893 and SKBR3 cells. Unlike lapatinib,
BYL719, and the combination of lapatinib + BYL719,
which induced formation and accumulation of GFP-LC3+
autophagosomes, SAR405 treatment did not cause the for-
mation and accumulation of GFP-LC3+ puncta (Fig. 5c).
Further, SAR405 effectively blocked the formation and ac-
cumulation of GFP-LC3+ autophagosomes induced by
lapatinib, BYL719, or their combination.
To examine the impact of pharmacological Vps34 in-
hibition on apoptosis, we treated SKBR3, BT474, and
UACC893 cells with SAR405 and measured caspase 3/7
activity as a quantitative surrogate for apoptosis. Caspase
3/7 activity was highest after 6 h of treatment in
UACC893 and BT474 cells and at 24 h in SKBR3
cells based on time course analyses (Additional file 3:
Figure S3A). SAR405 as a single agent modestly but sig-
nificantly increased caspase3/7 activity in BT474 and
SKBR3 cells (Fig. 5d). In all three cell lines, lapatinib treat-
ment robustly induced caspase 3/7 activity, as did
BYL719. However, Vps34 inhibition using SAR405 further
increased caspase 3/7 activity induced by lapatinib,
BYL719 or their combination. These results were con-
firmed using fluorescence-conjugated Annexin V, which
binds to phosphatidyl serine exposed on the outer
plasma membrane leaflet of dying cells (Additional
file 3: Figure S3B). All cell lines demonstrated <6 %
Annexin V-positive cells in the absence of inhibitors.
SAR405 used as a single agent did not affect the pro-
portion of cells binding to Annexin V (Fig. 5e), while
lapatinib increased the fraction of Annexin V-positive
cells to >20 % in UACC893 or BT474 cells and doubled
the number of Annexin V-positive SKBR3 cells. Similar to
what was seen with lapatinib, BYL719 used as a single
agent increased the proportion of Annexin V-positive
cells, and the combination of lapatinib + BY719 produced
a further increase in the Annexin V-positive cell popula-
tion in two of three HER2-amplified cell lines examined.
Notably, inhibition of Vps34 using SAR405 in combin-
ation with lapatinib, BYL719, or the combination of lapati-
nib + BYL719 drove the proportion of Annexin V-positive
cells even higher. In summary, the inhibition of Vps34 de-
creased proliferation and increased cell death induced by
either lapatinib or BYL719 in all three HER2+ cell lines,
with superior anti-tumor cell responses often observed
when HER2, p110α and Vps34 were simultaneously inhib-
ited. These data are consistent with the idea that Vps34
induces autophagy in HER2-amplified breast cancer cells
in response to type I PI3K pathway blockade as a stop gap
survival pathway. As such, inhibition of autophagosome
formation using type III PI3K inhibitors (like the Vps34
inhibitor) may enhance tumor cell killing in response to
type I PI3K pathway inhibition.
Discussion
HER2-amplified breast cancer cells are exquisitely de-
pendent on the type I PI3K signaling pathway, although
the role of type III PI3K is less clear. Combinations of
type I PI3K- and HER2-targeted therapeutics are being
tested in preclinical cancer models and in clinical trials
[11–13, 33–35]. We knocked down the type I PI3K cata-
lytic subunit p110α in HER2-amplified breast cancer
cells using EZN4150, a locked nucleic acid anti-sense
oligonucleotide [3]. EZN4150 has previously been shown
to block p110α expression in prostate cancer cell lines
[25] and in NSCLC xenografts [27]. We discovered that
EZN4150 targets both p110α and Vps34 in a sequence-
specific manner, thus inhibiting both class I p110α PI3K
signaling and pro-survival autophagy driven by class III
PI3K/Vps34 signaling, producing a potent induction of
tumor cell death.
As the only conserved member of the PI3K family in
all eukaryotes, Vps34 plays a pivotal role in regulating
membrane trafficking, including endocytosis, endosome-
lysosome maturation, autophagosome formation/flux
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Fig. 5 Simultaneous inhibition of human epidermal growth factor recptor-2 (HER2), p110α and Vps34 induces cell death in HER2+ breast cancer.
a UACC893, BT474 and SKBR3 cells were cultured with 1 μM SAR405, 0.5 μM Lapatinib or 0.5 μM BYL719. Relative cell number was determined by
sulforhodamine B assay at time 0 and after three days of culture. Day 3 signal divided by day 0 signal was used to normalize cell number to day
0. b Cells were treated as described in a. Lysates were harvested 6 h after treatment and analyzed by immunoblot analysis with the indicated
antibodies. c UACC893-GFP-LC3 cells were treated with 1 μM SAR405, 0.5 μM Lapatinib or 0.5 μM BYL719 for 3 h before being fixed and green
fluorescent protein (GFP)-LC3 localization determined by fluorescent microscopy. SKBR3-GFP-LC3 cells were analyzed similarly, but fixed after 6 h
of treatment. d, e UACC893 and BT474 cells were treated for 6 h and SKBR3 cells for treated 24 h with 1 μM SAR405, 0.5 μM Lapatinib or 0.5 μM
BYL719 before caspase 3/7 activity was determined (d) or stained with Annexin V (e). In all experiments, SAR405 was applied 30 minutes prior to
the application of BYL719, lapatinib or dimethyl sulfoxide (DMSO) control (*p <0.05, Student t test comparing the effect of DMSO vs. SAR405
within each treatment group)
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and cytokinesis [36]. Thus, this ancestral PI3K iso-
form is critical for nutrient acquisition, energy main-
tenance and cell division. These functions are
partially conserved in class I PI3K of higher eukary-
otes, with an example found in cancer cells: PI3K/Akt
activity regulates glucose uptake and metabolism, pro-
motes F-actin dynamics during invadopodia formation
and tumor cell invasion, and promotes tumor cell
survival [37–39]. However, class I PI3K/p110α signal-
ing activates mTOR and suppresses autophagy, thus
opposing the activity of class III PI3K/Vps34. This
highlights a functional divergence in class I and class
III PI3K families in higher eukaryotes [16], which is
utilized by tumor cells to promote mTOR-dependent
anabolic processes like DNA, lipid and protein syn-
thesis, or to maintain cellular energetics through
Vps34-dependent autophagy when mTOR is inhibited
[15, 18]. Thus, HER2/PI3K/mTOR inhibitors have
greater anti-tumor activity when combined with in-
hibitors of autophagy [19, 20, 22, 23, 32].
Similar to small molecule type I PI3K inhibitors in
other studies [12, 40], EZN4150 sensitized HER2+ breast
cancer cells to the HER2 TKI lapatinib. However, unlike
small molecule catalytic inhibitors of PI3K, EZN4150
did not induce autophagy, and even blocked the induc-
tion of autophagy in response to catalytic type I PI3K in-
hibitors [17, 31]. Because Vps34 plays a vital role in
cellular processes other than autophagy, we cannot rule
out that inhibition of other Vps34-dependent pathways
contributes to tumor cell apoptosis in response to
EZN4150 or SAR405. However, a chemical inhibitor of
autophagy flux, chloroquine, has been demonstrated to
enhance the effects of HER2 inhibitors [23] suggesting
that autophagy is playing a protective role in response to
drug treatment. These findings suggest that Vps34-
regulated autophagy promotes cell survival upon HER2
or PI3K pathway inhibition, and that blockade of au-
tophagy, using chloroquine or inhibitors of Vps34, im-
prove the antitumor effect of HER2/PI3K pathway
inhibitors.
Conclusions
These studies identify EZN4150 as an antisense oligo-
nucleotide that simultaneously targets p110α, a class I
PI3K, and Vps34, the class III PI3K. Targeted inhibition
of Vps34 using siRNA-mediated knockdown or pharma-
cological inhibition blocked the induction of autophagy
in response to HER2/PI3K inhibitors, thus increasing
therapeutic tumor cell killing in HER2-amplified breast
cancer cells. These findings warrant future studies exam-
ining Vps34 as a therapeutic target to improve tumor
cell apoptosis in combination with inhibitors of the
HER2/PI3K signaling axis.
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